JP2013538555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538555A5 JP2013538555A5 JP2013519216A JP2013519216A JP2013538555A5 JP 2013538555 A5 JP2013538555 A5 JP 2013538555A5 JP 2013519216 A JP2013519216 A JP 2013519216A JP 2013519216 A JP2013519216 A JP 2013519216A JP 2013538555 A5 JP2013538555 A5 JP 2013538555A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- isolated
- mhc class
- gad
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims 30
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 102000043131 MHC class II family Human genes 0.000 claims 23
- 108091054438 MHC class II family Proteins 0.000 claims 23
- 230000000599 auto-anti-genic effect Effects 0.000 claims 23
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108010010378 HLA-DP Antigens Proteins 0.000 claims 1
- 102000015789 HLA-DP Antigens Human genes 0.000 claims 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36444310P | 2010-07-15 | 2010-07-15 | |
| US61/364,443 | 2010-07-15 | ||
| PCT/IL2011/000564 WO2012007951A1 (en) | 2010-07-15 | 2011-07-14 | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538555A JP2013538555A (ja) | 2013-10-17 |
| JP2013538555A5 true JP2013538555A5 (enExample) | 2014-08-28 |
Family
ID=44504048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519216A Pending JP2013538555A (ja) | 2010-07-15 | 2011-07-14 | Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9695410B2 (enExample) |
| EP (1) | EP2593551B1 (enExample) |
| JP (1) | JP2013538555A (enExample) |
| BR (1) | BR112013000985A2 (enExample) |
| CA (1) | CA2805479A1 (enExample) |
| WO (1) | WO2012007951A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2593551B1 (en) | 2010-07-15 | 2016-09-14 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| US20150218546A1 (en) * | 2011-04-05 | 2015-08-06 | Lars Klareskog | Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| AU2014249148B2 (en) * | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| US12636346B2 (en) | 2015-09-21 | 2026-05-26 | Kolon Life Science, Inc. | Composition for treating pain |
| KR20170034701A (ko) * | 2015-09-21 | 2017-03-29 | 코오롱생명과학 주식회사 | 통증 치료용 조성물 |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| WO2019051126A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP7691927B2 (ja) * | 2019-03-06 | 2025-06-12 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 |
| WO2020181062A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN114206945B (zh) * | 2019-08-09 | 2025-11-04 | 弗劳恩霍夫应用研究促进协会 | Mhc ii/cii肽复合体的产生 |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CN116981357A (zh) | 2021-03-31 | 2023-10-31 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| WO2025021112A1 (zh) * | 2023-07-24 | 2025-01-30 | 佳吾益(北京)科技有限公司 | 开发mhc新抗原的工程化细胞 |
| CN119039446B (zh) * | 2024-10-30 | 2025-01-28 | 首都医科大学宣武医院 | 抗gad65抗体及其应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US6060309A (en) * | 1995-06-07 | 2000-05-09 | Anergen, Inc. | Immune mediators and related methods |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| DE19525784A1 (de) | 1995-07-14 | 1997-01-16 | Boehringer Mannheim Gmbh | Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD) |
| US5853723A (en) | 1995-09-21 | 1998-12-29 | University Of Utah Research Foundation | Targeting of peg antibody conjugates to islet cells |
| US6037137A (en) | 1997-02-20 | 2000-03-14 | Oncoimmunin, Inc. | Fluorogenic peptides for the detection of protease activity |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU5532601A (en) | 2000-04-12 | 2001-10-30 | Univ Rochester | Targeted vaccine delivery systems |
| EP1319184B1 (en) | 2000-08-14 | 2007-07-25 | N.V. Organon | Use of antibodies against specific mhc-peptide complexes |
| AU2003273219A1 (en) | 2002-07-12 | 2004-02-02 | Dana-Farber Cancer Institute, Inc. | Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange |
| WO2005044982A2 (en) | 2003-09-05 | 2005-05-19 | Oregon Health & Science University | Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| CA2574665C (en) | 2004-07-23 | 2014-07-15 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic and diagnostic agents |
| CA2638892A1 (en) * | 2005-03-18 | 2006-09-28 | Oregon Health & Science University | Recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| JP5650406B2 (ja) | 2007-03-07 | 2015-01-07 | ユーティーアイ リミテッド パートナーシップ | 自己免疫状態の予防および治療のための組成物および方法 |
| US20110008382A1 (en) | 2009-03-07 | 2011-01-13 | Burrows Gregory G | Compositions and methods using recombinant MHC molecules for the treatment of uveitis |
| CA2805478A1 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
| EP2593551B1 (en) | 2010-07-15 | 2016-09-14 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| EP2632955A1 (en) | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
-
2011
- 2011-07-14 EP EP11746670.6A patent/EP2593551B1/en not_active Not-in-force
- 2011-07-14 WO PCT/IL2011/000564 patent/WO2012007951A1/en not_active Ceased
- 2011-07-14 BR BR112013000985A patent/BR112013000985A2/pt not_active IP Right Cessation
- 2011-07-14 CA CA2805479A patent/CA2805479A1/en not_active Abandoned
- 2011-07-14 US US13/810,266 patent/US9695410B2/en not_active Expired - Fee Related
- 2011-07-14 JP JP2013519216A patent/JP2013538555A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535963A5 (enExample) | ||
| US20220380445A1 (en) | Serum albumin binders | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2012518425A5 (enExample) | ||
| US12269869B2 (en) | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof | |
| JP2023012516A (ja) | 抗ｉｌ２３抗体を使用してクローン病を治療するための方法 | |
| JP2012531212A5 (enExample) | ||
| CA2792740A1 (en) | Antibodies with ph dependent antigen binding | |
| JP2018502060A5 (enExample) | ||
| JP2021535733A5 (enExample) | ||
| JP2018527884A5 (enExample) | ||
| JP2018512145A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2013514788A5 (enExample) | ||
| RU2015141418A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| JP2019512207A5 (enExample) | ||
| JP2010529026A5 (enExample) | ||
| AU2019309948A1 (en) | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use | |
| JP2014515600A5 (enExample) | ||
| JP2022524204A (ja) | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 | |
| JP2023516925A5 (enExample) | ||
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| JP2017536821A5 (enExample) | ||
| JP2013508391A5 (enExample) | ||
| Gross et al. | CD19× CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease |